BioSpace News Archive

Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregivers living with liver cancer.

The approval was based on two randomized open-label clinical trials that evaluated the combination of empagliflozin, linagliptin and metformin and their individual components in healthy adults.

AI healthcare data-analytics startup H1 opens its first San Francisco office amidst record company growth

Approach expected to have broad applications in agriculture, industrial biotechnology, human healthcare

Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, announced it has initiated dosing for the last patient in a Phase 2b study of PTI-125.

Aphios Corporation announced that it was issued US Patent No. 10,493,030 for the treatment of HIV latency towards an HIV cure.

This is a pivotal time in the field of gene therapy as the FDA continues its efforts to support innovators developing new medical products for Americans and others around the world.

Immuron Limited announced the sales results of its commercially available and over-the-counter gastrointestinal and digestive health supplement Travelan® for the first half of fiscal year 2020 ending on December 31, 2019.

(EcoGen), the leading vertically-integrated manufacturer and supplier of hemp-derived specialty ingredients, proprietary formulations, and private-label finished products in the United States, announced today the closing of a $40 million private placement.

Catena to receive annual prestigious AMH Gerson L’Chaim Prize for ‘outstanding Christian medical missionary service’ from African Mission Healthcare